AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Outcomes of Section IIa STENOVA Research in Fibrosing Crohn’s Illness October 1, 2026 8:30 AM EDT
Firm Individuals
Tim Knotnerus – CEO & Government Director
Philippe Wiesel – Chief Medical Officer
Florian Rieder
Convention Name Individuals
Judah Frommer – Morgan Stanley, Analysis Division
Anupam Rama – JPMorgan Chase & Co, Analysis Division
Thomas Smith – Leerink Companions LLC, Analysis Division
Shannon Duffy
Ioannis Souroutzidis – Cantor Fitzgerald & Co., Analysis Division
Luis Santos – H.C. Wainwright & Co, LLC, Analysis Division
Sushila Hernandez – Kempen & Co. N.V., Analysis Division
William Wooden – B. Riley Securities, Inc., Analysis Division
Presentation
Operator
Good morning, everybody, and welcome to the AgomAb Therapeutics Digital Administration and KOL occasion. [Operator Instructions] As a reminder, this webinar is being recorded, and a replay will likely be made accessible on the AgomAb web site following the conclusion of the occasion.
Earlier than we start, we want to remind everybody that at present’s presentation comprises forward-looking statements. These statements are topic to dangers and uncertainties which will trigger precise outcomes to vary materially.
Please confer with AgomAb’s SEC filings for a dialogue of those dangers. I might now like to show the decision over to Tim Knotnerus, Chief Government Officer at AgomAb Therapeutics. Please go forward, Tim.
Tim Knotnerus
CEO & Government Director
Thanks a lot, Sarah, and thanks all for becoming a member of at present’s webcast to debate the open-label extension outcomes of the Section IIa STENOVA examine in sufferers with Fibrostenosing Crohn’s illness.
Let me introduce our audio system for at present. Very glad we’re joined by Dr. Rieder from the Cleveland Clinic, who can also be Chair of the STAR Consortium.
On the corporate facet, I am joined by Chief Medical Officer, Philippe Wiesel; and Chief Monetary Officer, Pierre Kemula. I am Tim Knotnerus, and thanks a lot for becoming a member of at present.
In the present day, I
